Phase 2RecruitingPriority 3 · Moderate priorityNCT02974647
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Plain-language summary
This trial is testing Ruxolitinib for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial is available at 10 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Ruxolitinib
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details